This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, C.-L. Articles by Ngan, H. Y. S. Search for Related Content PubMed PubMed Citation Articles by Chen, C.-L. Articles by Ngan, H. Y. S.

p73 Gene Expression in Ovarian Cancer Tissues and Cell Lines

Department of Obstetrics and Gynecology, The University of Hong Kong, Hong Kong, S. A. R., China

The p73 gene, a homology of p53, is a new candidate of imprinting and tumor suppressor gene. To investigate the role of p73 in ovarian cancer, we studied the allelic expression in 56 cases of ovarian cancer using StyI polymorphism analysis. We also examined p73 expression by semi-quantitative reverse transcription-PCR as well as by Western blot analysis and DNA methylation study of the CpG island in exon 1 in ovarian cancer tissues and cell lines. Loss of heterozygosity was found in 8.3% (2 of 24) of the cases. Biallelic expression was demonstrated in 91.7% (22 of 24) of the tumor samples, in 70.8% (17 of 24) of the normal samples, and in 1 ovarian cancer cell line. Imbalanced expression and monoallelic expression were found in three and two pairs of matched samples, respectively. Overexpression of p73 was found in advanced ovarian cancer rather than in early-stage disease or in borderline ovarian tumor. No significant difference was found in the p53 expression. Three cell lines with absent p73 protein expression and one tumor sample with monoallelic expression were methylated in the CpG island. Demethylation in SKOV3 cell line using 5-azacytidine can reactivate the expression of this gene in both the mRNA and the protein level. Our results indicated that p73 was not imprinted in most of the ovarian cancer and normal tissues, but it could be involved in the advanced ovarian cancer through overexpression. DNA methylation may contribute to the lack of p73 expression.

This article has been cited by other articles:

				J. M. Teodoridis, J. Hall, S. Marsh, H. D. Kannall, C. Smyth, J. Curto, N. Siddiqui, H. Gabra, H. L. McLeod, G. Strathdee, et al. CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer Cancer Res., October 1, 2005; 65(19): 8961 - 8967. [Abstract] [Full Text] [PDF]

				U. M. Moll and N. Slade p63 and p73: Roles in Development and Tumor Formation Mol. Cancer Res., July 1, 2004; 2(7): 371 - 386. [Abstract] [Full Text] [PDF]

				S. S. Liu, R. C.-Y. Leung, K. Y.-K. Chan, P.-M. Chiu, A. N.-Y. Cheung, K.-F. Tam, T.-Y. Ng, L.-C. Wong, and H. Y.-S. Ngan p73 Expression Is Associated with the Cellular Radiosensitivity in Cervical Cancer after Radiotherapy Clin. Cancer Res., May 15, 2004; 10(10): 3309 - 3316. [Abstract] [Full Text] [PDF]

				A Oniscu, N Sphyris, R G Morris, S Bader, and D J Harrison p73{alpha} is a candidate effector in the p53 independent apoptosis pathway of cisplatin damaged primary murine colonocytes J. Clin. Pathol., May 1, 2004; 57(5): 492 - 498. [Abstract] [Full Text] [PDF]

				N. Concin, K. Becker, N. Slade, S. Erster, E. Mueller-Holzner, H. Ulmer, G. Daxenbichler, A. Zeimet, R. Zeillinger, C. Marth, et al. Transdominant {Delta}TAp73 Isoforms Are Frequently Up-regulated in Ovarian Cancer. Evidence for Their Role as Epigenetic p53 Inhibitors in Vivo Cancer Res., April 1, 2004; 64(7): 2449 - 2460. [Abstract] [Full Text] [PDF]

				Y. Sasaki, H. Mita, M. Toyota, S. Ishida, I. Morimoto, T. Yamashita, T. Tanaka, K. Imai, Y. Nakamura, and T. Tokino Identification of the Interleukin 4 Receptor {alpha} Gene as a Direct Target for p73 Cancer Res., December 1, 2003; 63(23): 8145 - 8152. [Abstract] [Full Text] [PDF]

				M. Guan, H.-X. Peng, B. Yu, and Y. Lu p73 Overexpression and Angiogenesis in Human Colorectal Carcinoma Jpn. J. Clin. Oncol., May 1, 2003; 33(5): 215 - 220. [Abstract] [Full Text] [PDF]

				T. Stiewe, J. Stanelle, C. C. Theseling, B. Pollmeier, M. Beitzinger, and B. M. Putzer Inactivation of Retinoblastoma (RB) Tumor Suppressor by Oncogenic Isoforms of the p53 Family Member p73 J. Biol. Chem., April 11, 2003; 278(16): 14230 - 14236. [Abstract] [Full Text] [PDF]

				T. Stiewe, S. Zimmermann, A. Frilling, H. Esche, and B. M. Putzer Transactivation-deficient {Delta}TA-p73 Acts as an Oncogene Cancer Res., July 1, 2002; 62(13): 3598 - 3602. [Abstract] [Full Text] [PDF]

				K.-i. Watanabe, T. Ozaki, T. Nakagawa, K. Miyazaki, M. Takahashi, M. Hosoda, S. Hayashi, S. Todo, and A. Nakagawara Physical Interaction of p73 with c-Myc and MM1, a c-Myc-binding Protein, and Modulation of the p73 Function J. Biol. Chem., April 19, 2002; 277(17): 15113 - 15123. [Abstract] [Full Text] [PDF]

				T. Nakagawa, M. Takahashi, T. Ozaki, K.-i. Watanabe, S. Todo, H. Mizuguchi, T. Hayakawa, and A. Nakagawara Autoinhibitory Regulation of p73 by {Delta}Np73 To Modulate Cell Survival and Death through a p73-Specific Target Element within the {Delta}Np73 Promoter Mol. Cell. Biol., April 15, 2002; 22(8): 2575 - 2585. [Abstract] [Full Text] [PDF]